The Fly

FDA revises EUA for Paxlovid to remove SARS-CoV-2 viral testing requirement

The FDA issued a fact sheet for healthcare providers on the Emergency Use Authorization for Pfizer’s Paxlovid, which indicates that the EUA has been revised to remove a previous requirement of SARS-CoV-2 viral testing. Reference Link

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on PFE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More